1. Home
  2. ICON vs DCOY Comparison

ICON vs DCOY Comparison

Compare ICON & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Icon Energy Corp.

ICON

Icon Energy Corp.

HOLD

Current Price

$0.85

Market Cap

4.5M

Sector

N/A

ML Signal

HOLD

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$6.11

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICON
DCOY
Founded
2023
N/A
Country
Greece
United States
Employees
N/A
11
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ICON
DCOY
Price
$0.85
$6.11
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$30.00
AVG Volume (30 Days)
112.8K
12.6K
Earning Date
02-24-2026
05-16-2026
Dividend Yield
4754.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.33
N/A
Revenue Next Year
$23.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.53
52 Week High
$4.23
$9.57

Technical Indicators

Market Signals
Indicator
ICON
DCOY
Relative Strength Index (RSI) 31.34 47.85
Support Level $0.81 $4.98
Resistance Level $1.24 $6.47
Average True Range (ATR) 0.08 0.78
MACD -0.02 -0.08
Stochastic Oscillator 15.70 36.33

Price Performance

Historical Comparison
ICON
DCOY

About ICON Icon Energy Corp.

Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Share on Social Networks: